Financial Data and Key Metrics Changes - Organic sales for fiscal year 2025 grew by 2%, with volume growth contributing 1% and price mix adding another 1% [11] - Core earnings per share (EPS) reached $6.83, up 4% year-over-year [14] - Core gross margin declined by 40 basis points, while core operating margin increased by 50 basis points [14] - Adjusted free cash flow productivity was 87%, with $16 billion returned to shareholders, including $10 billion in dividends and $6.5 billion in share repurchases [15] Business Line Data and Key Metrics Changes - Nine out of ten product categories experienced organic sales growth, with Family Care and Personal Healthcare growing in the low single digits [11] - Baby Care saw a decline in organic sales in the low singles [11] - E-commerce sales increased by 12%, now representing 19% of total company sales [12] Market Data and Key Metrics Changes - Focus markets grew organic sales by 2%, with North America up 2% and Europe focus markets up 3% [12] - Greater China organic sales were down 5% year-over-year but improved sequentially, growing 2% in the most recent quarter [12] - Enterprise markets grew by 2%, led by Latin America with 4% organic sales growth [12] Company Strategy and Development Direction - The company is focused on an integrated growth strategy that emphasizes balanced top and bottom line growth and value creation [7][25] - A restructuring program was announced to strengthen execution and improve organizational capabilities [39] - The company aims to capture significant growth opportunities in North America, Europe, and enterprise markets, with potential sales opportunities ranging from $5 billion to $15 billion [24][25] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenging macroeconomic environment, including tariffs, inflation, and geopolitical dynamics, which have impacted category growth [23] - The company expects the market environment to remain volatile and challenging in fiscal year 2026, with guidance for organic sales growth in the range of flat to 4% [45][46] - Management emphasized the importance of creating "tailwinds" through innovation and strategic investments to drive growth [58] Other Important Information - The company plans to reduce up to 7,000 non-manufacturing roles, or roughly 15% of its current non-manufacturing workforce, as part of the restructuring efforts [42] - The transition of leadership from Jon Moeller to Shailesh Jujurukar is planned for January 1, 2026, with a focus on continuity and strategic execution [5][56] Q&A Session Summary Question: Insights on Shailesh's leadership and tailwind creation efforts - Management highlighted Shailesh's extensive experience and leadership capabilities as key to driving future growth and value creation [56][58] Question: Addressing the narrowing performance gap in North America - Management acknowledged the reduction in category growth rates and the need to regain superiority in certain categories to widen the performance gap [65][66] Question: Timing and impact of restructuring on organizational capabilities - Management explained that the restructuring aims to enhance decision-making and efficiency, leveraging technology to break down silos within the organization [81][84]

Financial Data and Key Metrics Changes - In Q2 2025, worldwide sales reached $23.7 billion, reflecting a 4.6% increase despite a headwind from Stellara [24][25] - Net earnings for the quarter were $5.5 billion, with diluted earnings per share of $2.29, up from $1.93 a year ago [25][26] - Adjusted net earnings were $6.7 billion, with adjusted diluted earnings per share of $2.77, representing a decrease of 2.1% [26][34] Business Line Data and Key Metrics Changes - Innovative Medicine reported worldwide sales of $15.2 billion, increasing by 3.8% despite a headwind from Stellara [26][27] - MedTech achieved worldwide sales of $8.5 billion, reflecting a 6.1% increase, driven by strong performance in cardiovascular, surgery, and vision [30][31] - In oncology, DARZALEX grew by 21.5%, while CARVICTI saw over 100% growth [27][28] Market Data and Key Metrics Changes - U.S. sales growth was 7.6%, while international sales experienced a decline of 1.6% due to Stellara biosimilars and COVID-19 vaccine impacts [26][27] - The cardiovascular segment in MedTech delivered over 22% operational sales growth, driven by new product performance [18][30] Company Strategy and Development Direction - The company aims to become the number one oncology company by 2030, targeting over $50 billion in sales [11][72] - Focus areas include oncology, immunology, neuroscience, cardiovascular, surgery, and vision, with a commitment to innovation and addressing unmet medical needs [10][21] - The company plans to launch several new products and therapies in the second half of 2025, including TAR200 for bladder cancer and subcutaneous Ribrovant for lung cancer [49][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving and potentially exceeding growth targets for 2025, driven by strong performance in both Innovative Medicine and MedTech [39][42] - The company anticipates an acceleration in operational sales growth in the second half of the year, supported by new product launches and market share gains [42][60] - Management highlighted the importance of navigating external challenges while maintaining financial commitments and delivering shareholder value [51][52] Other Important Information - The company raised its full-year sales guidance by $2 billion and EPS guidance by $0.25, reflecting strong Q2 performance [9][42] - The effective tax rate for the quarter was 14.7%, down from 18.5% in the previous year [35][36] - The company ended Q2 with $19 billion in cash and marketable securities and $51 billion in debt, resulting in a net debt position of $32 billion [40] Q&A Session Summary Question: Drivers of upside to guidance for the year - Management indicated that both Innovative Medicine and MedTech contributed to strong performance, with notable growth in brands like DARZALEX and CARVICTI [54][55] Question: Oncology target of $50 billion by the end of the decade - Management expressed confidence in achieving the target, citing strong growth in multiple myeloma and the potential of TAR200 for bladder cancer [70][72] Question: Guidance for top-line growth acceleration - Management expects 2026 to show better growth rates than 2025, driven by new product introductions and market dynamics [84][86]